BlackRock Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

BlackRock Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.22M	Buy	64,697 +24,708	+62%	+$605K	﹤0.01%	2034
2016 Q3	$1.2M	Buy	39,989 +4,553	+13%	+$142K	﹤0.01%	1935
2016 Q2	$1.36M	Buy	35,436 +783	+2%	+$32.5K	﹤0.01%	1794
2016 Q1	$1.32M	Buy	34,653 +4,609	+15%	+$161K	﹤0.01%	1778
2015 Q4	$1.32M	Buy	30,044 +29,093	+3,059%	+$1.44M	﹤0.01%	1717
2015 Q3	$39K	Sell	951 -1,451	-60%	-$63.6K	﹤0.01%	2892
2015 Q2	$129K	Buy	2,402 +2,071	+626%	+$110K	﹤0.01%	2689
2015 Q1	$20K	Sell	331 -36,755	-99%	-$1.78M	﹤0.01%	2818
2014 Q4	$1.94M	Buy	+37,086	New	+$1.66M	﹤0.01%	1492

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's JUNO Position: Q4 2016 in Review

BlackRock Group increased its Juno Therapeutics, Inc. (JUNO) stake by 62% in Q4 2016, buying an estimated $605K and bringing the position to 64,697 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2034.

BlackRock Group first reported a position in JUNO in Q4 2014 and has held it in 9 quarters since. The position peaked at $1.94M in Q4 2014. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

BlackRock Group held 64,697 shares of Juno Therapeutics, Inc. worth $1.22M as of Q4 2016.
BlackRock Group bought 24,708 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $605K.
Juno Therapeutics, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2034 holding.
BlackRock Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and has held it in 9 quarters since.
BlackRock Group's Juno Therapeutics, Inc. position peaked at $1.94M in Q4 2014.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.